Intercell and Merck: Strategic alliance to develop monoclonal antibodies for the treatment of Staphylococcus aureus infections
Under the terms of an agreement signed in May 2004, Merck has exercised an option to receive worldwide rights to develop and commercialize antibodies directed against proprietary antigens that have been detected by Intercell's Antigen Identification Program (AIP®). This technology identifies antibacterial targets. Pursuant to the agreement, Merck Inc. is responsible for subsequent preclinical and clinical development, registration and marketing of the product.
Intercell is entitled to an option exercise fee and additional milestone payments. Furthermore, Intercell will receive royalties on future sales of the product. There are no further costs involved for Intercell.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous